Evidence map›Paper›PMID 23638978›Full record

Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2014

A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis.

T R Hata, D Audish, P Kotol, A Coda, F Kabigting, J Miller, D Alexandrescu, M Boguniewicz, P Taylor, L Aertker and 4 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00789880 (Analysis of the Response of Subjects With Atopic Dermatitis to Oral Vitamin D3 by Measurement of Antimicrobial Peptide Expression in Skin and Saliva), which is not on this map. Cited by 36 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 6 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00789880 phase2completednot on this map

Analysis of the Response of Subjects With Atopic Dermatitis to Oral Vitamin D3 by Measurement of Antimicrobial Peptide Expression in Skin and Saliva

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2008 to 2009Enrolled82ConditionsAtopic Dermatitis, PsoriasisArmsVitamin D3, Placebo
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 6 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Neutrophils in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2024
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Potential Genes Associated with COVID-19 and Comorbidity.International journal of medical sciences · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

T R HataDivision of Dermatology, Department of Medicine, University of California San Diego and VA Healthcare System, San Diego, CA.
D Audish
P Kotol
A Coda
F Kabigting
J Miller
D Alexandrescu
M Boguniewicz
P Taylor
L Aertker
K Kesler
J M Hanifin
D Y M Leung
R L Gallo
University of California, San Diego · USNational Jewish Health · USVA San Diego Healthcare System · USRho (United States) · USOregon Health & Science University · US

Funding

Atopic Dermatitis and Vaccinia Immunization Network Clinical ConsortiumN01AI40029 · NIAID · NATIONAL JEWISH HEALTH · 2008 to 2010
$8.6M
Statistical and Data Coordinating Center for the ADVNN01AI40033 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI ATHEY, CAROL · 2008 to 2014
$6.2M
Cathelicidins in Skin ImmunityR01AI052453 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GALLO, RICHARD L, NIZET, VICTOR · 2002 to 2017
$5.3M
Cathelicidin in Skin ImmunityR37AI052453 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Richard L Gallo, Victor Nizet · 2019 to 2026
$4.6M
ATOPIC DERMITITIS VACCINIA NETWORK /ADVN/-266040029N01AI040029 · NIAID · NATIONAL JEWISH MEDICAL AND RESEARCH CEN · PI LEUNG, DONALD YM · 2006 to 2006
–
NIAID NIH HHS HHSN266200400029CNIAID NIH HHS N01 AI040029NIAID NIH HHS N01 AI040033NIAID NIH HHS N01 AI 40029NIAID NIH HHS N01 AI40033NIAID NIH HHS R01 AI052453NIAID NIH HHS R37 AI052453
6 · The paper itself

Abstract

backgroundSubjects with atopic dermatitis (AD) have defects in antimicrobial peptide (AMP) production possibly contributing to an increased risk of infections. In laboratory models, vitamin D can alter innate immunity by increasing AMP production.

objectiveTo determine if AD severity correlates with baseline vitamin D levels, and to test whether supplementation with oral vitamin D alters AMP production in AD skin.

methodsThis was a multi-centre, placebo-controlled, double-blind study in 30 subjects with AD, 30 non-atopic subjects, and 16 subjects with psoriasis. Subjects were randomized to receive either 4000 IU of cholecalciferol or placebo for 21 days. At baseline and day 21, levels of 25-hydroxyvitamin D (25OHD), cathelicidin, HBD-3, IL-13, and Eczema Area and Severity Index (EASI) and Rajka-Langeland scores were obtained.

resultsAt baseline, 20% of AD subjects had serum 25OHD below 20 ng/mL. Low serum 25OHD correlated with increased Fitzpatrick Skin Type and elevated BMI, but not AD severity. After 21 days of oral cholecalciferol, mean serum 25OHD increased, but there was no significant change in skin cathelicidin, HBD-3, IL-13 or EASI scores.

conclusionsThis study illustrated that darker skin types and elevated BMI are important risk factors for vitamin D deficiency in subjects with AD, and highlighted the possibility that seasonality and locale may be potent contributors to cathelicidin induction through their effect on steady state 25OHD levels. Given the molecular links between vitamin D and immune function, further study of vitamin D supplementation in subjects with AD is warranted.

Indexed as

Dietary SupplementsAdultCholecalciferolDermatitis, AtopicDouble-Blind MethodFemaleHumansMaleSeverity of Illness IndexVitamin DVitamins25-hydroxyvitamin DCholecalciferolVitamin DVitamins

Identifiers

PMID23638978
PMCPMC3769441
OpenAlexW2098825396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.